Milestone Pharmaceuticals (MIST) Preferred Stock Liabilities (2018 - 2019)

Milestone Pharmaceuticals (MIST) posted Preferred Stock Liabilities of -$64.7 million for Q2 2019, down 476.32% on a QoQ basis from $17.2 million in Q1 2019, and down 611.9% year-over-year from $12.6 million in Q2 2018.

Milestone Pharmaceuticals (MIST) Preferred Stock Liabilities (2018 - 2019) Analysis & Trends

Milestone Pharmaceuticals' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at -$64.7 million for Q2 2019.

  • Quarterly Preferred Stock Liabilities fell 611.9% year-over-year to -$64.7 million in Q2 2019, while the trailing twelve-month figure through Jun 2019 was -$64.7 million (down 611.9% YoY) and the FY2018 annual result came in at $138.8 million, changed N/A from the prior year.
  • Preferred Stock Liabilities was -$64.7 million for Q2 2019 at Milestone Pharmaceuticals, down from $17.2 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $138.8 million in Q4 2018 and bottomed at -$64.7 million in Q2 2019.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Milestone Pharmaceuticals 156.34 Mn -27.87 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2019 -64.72 Mn
Mar 31, 2019 17.20 Mn
Dec 31, 2018 138.76 Mn
Sep 30, 2018 2.03 Mn
Jun 30, 2018 12.64 Mn
Mar 31, 2018 12.64 Mn